Describe your thoughts on SERENITY1 and SERENITY2 Phase 3 results. Does a product with this onset of action and duration seem attractive?

How would you see a product like this fitting into your practice? Is this something you would want to adopt right away or would you be cautious in using it? How do you feel about the sublingual thin film delivery?

How do you feel about the safety profile of the drug? Is it something you would feel comfortable with in Schizophrenia/Bipolar?

If possible, describe if you feel this mechanism of action (alpha2 agonist) would translate to acute agitation in Dementia (all forms including AD)? Would you feel comfortable using it if a lower dose showed comparable efficacy to 120mg/180mg doses in Schizophrenia/Bipolar?

If possible, describe if you feel this mechanism of action would also translate to their other planned indications of Opioid withdrawal symptoms and Delirium.

If you feel comfortable, describe what costs this drug would your save your practice or the healthcare system which would justify any potential pricing power? Specifically describe if you feel this product would be adopted by institutions and/or covered by private payers?

For Schizophrenia/bipolar, where would this product be used given it's safety/efficacy and focus on mild-moderate agitation? ER only? Urgent care? Private psychiatric office? Home? Would patients be able to self-medicate at home once getting agitated?

Given the data seen so far, if possible would you have an opinion about use in patients with dementia?